BackVir Biotechnology Overview

Vir Biotechnology Long Term Debt

Track Vir Biotechnology's long-term debt ($81M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$81.46M
↓ 10.70% YoYΔ $-9.76M vs prior year quarter

Peer trimmed avg / median

Loading

Vir Biotechnology Long Term Debt History

Loading

Vir Biotechnology vs. peers: Long Term Debt Comparison

Loading

Vir Biotechnology Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Vir Biotechnology (VIR) FAQ

Vir Biotechnology posts a long-term debt of $81M as of September 2026. That compares with $91M in the prior-year period — down 10.7% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Vir Biotechnology's long-term debt was $91M. The latest reading is $81M — a 10.7% year-over-year decrease (period ending September 2026). Use the history and growth charts on this page for a longer lookback.

Long-Term Debt is one piece of Vir Biotechnology's financial statement story. At $81M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for VIR's long-term debt usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Vir Biotechnology's other metric pages and overview cover the third.

Judging Vir Biotechnology against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in long-term debt easier to interpret. Start with $81M here, then scan peer and history charts to see if the gap is persistent.